| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Stem cell therapy for diabetes: Advances, prospects, and challenges
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dian-Bao Zuo, Chun-Hua Wang, Ming Sang, Xiao-Dong Sun, Guo-Ping Chen and Kang-Kang Ji |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Faculty Development Grants of Xiangyang No. 1 People’s Hospital Affiliated to Hubei University of Medicine |
No. XYY2025D05 |
| Faculty Development Grants of Xiangyang No. 1 People’s Hospital Affiliated to Hubei University of Medicine |
No. 2024QDJZR037 |
| Faculty Development Grants of Xiangyang No. 1 People’s Hospital Affiliated to Hubei University of Medicine |
No. 2024QDJZR015 |
|
| Corresponding Author |
Kang-Kang Ji, Chief Physician, MD, PhD, Postdoctoral Fellow, Professor, Department of Clinical Medical Research, Binhai County People’s Hospital, Clinical Medical College of Yangzhou University, No. 299 Haibin Road, Yancheng 224500, Jiangsu Province, China. kyrie@mail.ustc.edu.cn |
| Key Words |
Diabetes mellitus; Stem cell therapy; Induced pluripotent stem cells; Mesenchymal stem cells; Clinical applications |
| Core Tip |
Diabetes mellitus, affecting 830 million adults globally, remains inadequately addressed by conventional therapies that fail to halt β-cell loss or reverse insulin resistance. Stem cell therapy emerges as a transformative approach, leveraging dual mechanisms: Differentiation into glucose-responsive β-cells [e.g., induced pluripotent stem cells (iPSC)-derived islet transplantation achieving insulin independence in clinical trials] and immunomodulation via paracrine signaling [e.g., mesenchymal stem cells (MSC)-mediated suppression of autoimmunity in type 1 diabetes mellitus and chronic inflammation in type 2 diabetes mellitus]. Recent advancements include vertex pharmaceuticals’ VX-880 trial, where patients demonstrated restored insulin production and a significant reduction in exogenous insulin dependence (phase 1/2 trial NCT04786262 reported 11/12 patients reducing or eliminating insulin use by 2024). Peking University’s chemically reprogrammed iPSC-derived islet transplantation sustained normoglycemia for over a year. Challenges such as tumorigenicity in PSCs and immune rejection are addressed through clustered regularly interspaced short palindromic repeats-edited human leukocyte antigen knockouts and encapsulation technologies. Innovations like three dimensional-bioprinted organoids and artificial intelligence-driven personalized regimens integrating MSC-pharmacotherapy synergies exemplify the next frontier, promising scalable, precision solutions to redefine diabetes management and mitigate complications. |
| Publish Date |
2025-07-15 08:26 |
| Citation |
<p>Zuo DB, Wang CH, Sang M, Sun XD, Chen GP, Ji KK. Stem cell therapy for diabetes: Advances, prospects, and challenges. <i>World J Diabetes</i> 2025; 16(7): 107344</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i7/107344.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i7.107344 |
